FIELD: medicine.
SUBSTANCE: what is presented is using magnesium salt of comenic acid as a preventive and therapeutic agent in an amount of 2 mg per 1 kg of body weight for 3 days orally on an empty stomach once a day.
EFFECT: there are shown antioxidant and neuroprotective activities of magnesium comenate, as well as its stimulant action on the growth processed of spinal ganglia exceeding that of the action of comenic acid.
7 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACOLOGICAL NEUROPROTECTIVE DRUG | 2014 |
|
RU2561045C1 |
| ANTIOXIDANT, STRESS- AND NEUROPROTECTIVE PHARMACOLOGICAL AGENT POTASSIUM COMENATE | 2012 |
|
RU2514632C1 |
| METHOD FOR PREPARING LITHIUM SALT OF COMENIC ACID AND USING IT AS ANTIOXIDANT, STRESS- AND NEUROPROTECTIVE AGENT | 2011 |
|
RU2477722C1 |
| ANTIOXIDANT, STRESS AND NEUROPROTECTIVE PHARMACOLOGICAL AGENT SODIUM COMENATE | 2012 |
|
RU2506078C1 |
| NEUROPROTECTIVE AGENT | 2016 |
|
RU2614697C1 |
| METHOD OF PREVENTING AND CORRECTION OF DISTURBANCES OF MAIN FUNCTIONS OF CENTRAL NERVOUS SYSTEM IN CASE OF LEAD INTOXICATION IN PRENATAL AND EARLY POSTPARTUM PERIOD | 2009 |
|
RU2410107C1 |
| METHOD FOR PREVENTING AND CORRECTING METABOLIC AND FUNCTIONAL DISORDERS OF THE CENTRAL NERVOUS SYSTEM UNDER STRESS CONDITIONS | 2019 |
|
RU2717107C1 |
| COMBINED DRUG FOR PRIMARY NEUROPROTECTION | 2017 |
|
RU2636616C1 |
| PHARMACEUTICAL COMPOSITION FOR TREATING CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS OF CARDIOVASCULAR, TRAUMATIC, TOXIC, HYPOXIC AND AUTOIMMUNE GENESIS | 2010 |
|
RU2445106C1 |
| REGENERATING RESOLVENT AND WAYS OF TREATMENT BY MEANS OF THIS AGENT | 2007 |
|
RU2362554C2 |
